Unoprostone
Chemical compound
- S01EE02 (WHO)
- US: Discontinued
- (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)
cyclopentyl]hept-5-enoic acid
- 120373-36-6
Y 120373-24-2 (isopropyl ester)
- 5311236
- DB06826
N
- 4470755 N
- 6X4F561V3W
- D08661 Y
- ChEMBL1201407 N
- DTXSID80905120
- Interactive image
- O=C(O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CCC(=O)CCCCCCC
InChI
- InChI=1S/C22H38O5/c1-2-3-4-5-8-11-17(23)14-15-19-18(20(24)16-21(19)25)12-9-6-7-10-13-22(26)27/h6,9,18-21,24-25H,2-5,7-8,10-16H2,1H3,(H,26,27)/b9-6-/t18-,19-,20+,21-/m1/s1N
- Key:TVHAZVBUYQMHBC-SNHXEXRGSA-NN
N
Y (what is this?) (verify)Unoprostone (INN) is a prostaglandin analogue. Its isopropyl ester, unoprostone isopropyl, was marketed under the trade name Rescula for the management of open-angle glaucoma and ocular hypertension.[1][2]
It was approved by the Food and Drug Administration in 2000.[3]
In 2009, Sucampo Pharmaceuticals acquired the rights to the drug in the U.S. and Canada.[4]
In 2015, the drug was discontinued in the U.S.[citation needed]
References
- ^ Micromedex Detailed Consumer Information
- ^ Fung DS, Whitson JT (2014). "An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy". Clinical Ophthalmology. 8. Auckland, N.Z.: 543–54. doi:10.2147/OPTH.S41562. PMC 3958522. PMID 24648719.
- ^ "Drug Approval Package". Food and Drug Administration.
- ^ "Sucampo Pharmaceuticals, Inc. Acquires Rights to Rescula for U.S. and Canada" (Press release). Business Wire. April 24, 2009.
- v
- t
- e
- Apraclonidine
- Brimonidine (+timolol)
- Clonidine
- Dipivefrine
- Epinephrine
| muscarinic | |
|---|---|
| muscarinic/nicotinic | |
| acetylcholinesterase inhibitors |
(sulfonamides)
- Bimatoprost (+timolol)
- Latanoprost (+netarsudil, +timolol)
- Latanoprostene bunod
- Tafluprost
- Travoprost (+timolol)
- Unoprostone
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
